Literature DB >> 12817074

LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy.

Władysław Sułowicz1, Tomasz Stompór.   

Abstract

Plasma exchange was used for many years as the method of extracorporeal removal of antibodies and/or immune complexes that may be involved in the pathogenesis of renal diseases. Recently low-density lipoprotein (LDL)-apheresis and immunoadsorption were also introduced into nephrological practice. LDL-apheresis, designed originally as a rescue treatment for refractory hyperlipidaemia, appeared also to be effective in certain glomerulopathies, resistant to other treatment strategies. Similarly, immunoadsorption can be employed successfully in the treatment of different nephropathies, of both immunological and non-immunological pathogenesis. This method may also be effective as rescue treatment in some cases of acute rejection and recurrence of certain nephropathies after renal transplantation. The major advantage of both methods is their increased selectivity compared with standard plasma exchange. In addition, these techniques need no supplement fluid (namely fresh frozen plasma), which allows for markedly increased efficacy of the treatment as well as substantial reduction of infection risks.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12817074     DOI: 10.1093/ndt/gfg1050

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  Low-density lipoprotein apheresis ameliorates monthly estimated glomerular filtration rate declines in patients with renal cholesterol crystal embolism.

Authors:  Keiji Hirai; Susumu Ookawara; Haruhisa Miyazawa; Kiyonori Ito; Yuichirou Ueda; Yoshio Kaku; Taro Hoshino; Izumi Yoshida; Kaoru Tabei
Journal:  J Artif Organs       Date:  2014-11-04       Impact factor: 1.731

2.  Accelerated recovery from nephrotic syndrome with acute renal failure by double filtration plasmapheresis in a patient with lupus podocytopathy.

Authors:  Yoshitaka Iwazu; Tetsu Akimoto; Sayoko Izawa; Makoto Inoue; Shigeaki Muto; Yasuhiro Ando; Kana Iwazu; Noriyoshi Fukushima; Wako Yumura; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2012-02-18       Impact factor: 2.801

3.  Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report.

Authors:  Gianpaolo Russi; Luciana Furci; Marco Leonelli; Riccardo Magistroni; Nicola Romano; Paolo Rivasi; Alberto Albertazzi
Journal:  J Med Case Rep       Date:  2009-12-02

Review 4.  Beneficial effect of LDL-apheresis in refractory nephrotic syndrome.

Authors:  Eri Muso
Journal:  Clin Exp Nephrol       Date:  2014-02-18       Impact factor: 2.801

5.  Effect of Genistein and L-Carnitine and Their Combination on Gene Expression of Hepatocyte HMG-COA Reductase and LDL Receptor in Experimental Nephrotic Syndrome.

Authors:  Abbas Yousefinejad; Fereydoon Siassi; Abbas Mirshafiey; Mohammad-Reza Eshraghian; Fariba Koohdani; Mohammad Hassan Javanbakht; Reza Sedaghat; Atena Ramezani; Mahnaz Zarei; Mahmoud Djalali
Journal:  Iran J Public Health       Date:  2015-10       Impact factor: 1.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.